Share this article on:


Molina Ordas, A1; Rodriguez Gomez, A; Heras Benito, M; Fernandez-Reyes Luis, MJ; Sanchez Hernandez, R; Alvarez-Ude Cotera, F

doi: 10.1097/01.hjh.0000379832.13474.69
Poster Session 32: Neural Mechanisms

Gestational hypertension is not an uncommon situation. Previous studies have shown up hypertensive disorders complicate 5 to 10 percent of pregnancies. Multiple risk factors in gestational hypertension development have been described, just as: previous obstetrical preeclampsia history, first pregnancy, age, hypertension family history, obesity, multiple gestation… We have collected all gestational hypertension cases and its clinical and laboratory findings from our hospital between 1st January 2003 and 31st December 2009. We have evaluated 46 women. As a result of, we have found out the hypertension beginning was of 24.02 +/− 12.36 weeks. The gestation ending was of 36.65 +/− 2.70 weeks [5% women by caesarean section]. 15 women [32.6%] had developed hypertension in previous pregnancy and 17 [37%] had hypertension familiar history. Only 6 women [15.9%] were diabetic or had developed gestational diabetes. The most frequent antihypertensive treatment was Captopril [85.4%] followed by nifedipine [34,8%], labetalol [30.4%], and methyldopa [15.2%]. The most frequent laboratory findings were low levels of albumin [3.18 +/− 0.53], proteinuria [1.20 +/− 1.82] and a rise level in LDH [520.65 +/− 408], uric [6.02 +/− 1.7], and AST [44.13 +/− 87.36], ALT [44.35 +/− 72.06]. Hypertension familiar history patients have a bigger proteinuria [p = 0.06]. It was more frequent the hypertension development of a previous gestation [p = 0.024] and hypertension beginning after gestation [p = 0.014]. The gestational hypertension beginning was earlier in women with a previous pregnancy hypertension history [p = 0.001]. Finally, patients who required methyldopa treatment ended their pregnancy before the others [p = 0.039].

1Hospital General de Segovia, Segovia, Spain

© 2010 Lippincott Williams & Wilkins, Inc.